Repligen (NASDAQ:RGEN) Issues FY 2026 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 1.930-2.010 for the period, compared to the consensus estimate of 2.060. The company issued revenue guidance of $810.0 million-$840.0 million, compared to the consensus revenue estimate of $822.8 million.

Repligen Stock Performance

RGEN stock opened at $135.40 on Tuesday. Repligen has a twelve month low of $102.96 and a twelve month high of $175.77. The company has a quick ratio of 7.14, a current ratio of 8.36 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.62 billion, a P/E ratio of 6,773.39, a price-to-earnings-growth ratio of 2.48 and a beta of 1.13. The business’s fifty day moving average is $156.30 and its 200-day moving average is $146.71.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The business had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts forecast that Repligen will post 1.72 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on RGEN shares. Canaccord Genuity Group increased their price target on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Wednesday, October 29th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the company a “hold” rating in a research note on Tuesday, October 28th. Barclays lifted their price target on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. UBS Group upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $177.92.

Insider Activity

In related news, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the sale, the director directly owned 91,821 shares in the company, valued at $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.20% of the stock is owned by corporate insiders.

Institutional Trading of Repligen

Several hedge funds and other institutional investors have recently modified their holdings of the company. Compound Planning Inc. acquired a new position in shares of Repligen during the 4th quarter worth about $204,000. Mercer Global Advisors Inc. ADV bought a new stake in Repligen during the fourth quarter worth about $204,000. Polar Capital Holdings Plc acquired a new position in Repligen during the fourth quarter valued at approximately $202,000. Tower Research Capital LLC TRC boosted its position in Repligen by 14.1% during the second quarter. Tower Research Capital LLC TRC now owns 1,448 shares of the biotechnology company’s stock valued at $180,000 after purchasing an additional 179 shares during the last quarter. Finally, Advisory Services Network LLC bought a new position in Repligen in the third quarter valued at approximately $169,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.